Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
35 hedge funds and large institutions have $110M invested in Elevation Oncology in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
59% more funds holding
Funds holding: 22 → 35 (+13)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
10.42% more ownership
Funds ownership: 68.37% → 78.79% (+10%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
11% less capital invested
Capital invested by funds: $123M → $110M (-$13.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$1.73M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$151K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$148K |
| 4 |
Jane Street
New York
|
+$144K |
| 5 |
Renaissance Technologies
New York
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$3.24M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.9M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$559K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$320K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$190K |
ELEV Hedge Fund Activity: Q4 2021 in Review
35 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q4 2021, worth a combined $110M — down 11% from $123M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ELEV positions and 2 closed out — a net gain of 13 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $1.73M. The largest seller was Boxer Capital, cutting an estimated $3.24M.
- 35 institutional investors held Elevation Oncology (ELEV) as of Q4 2021, up from 22 in Q3 2021.
- Funds reported $110M of Elevation Oncology stock for Q4 2021, down 11% quarter-over-quarter.
- 15 funds opened new Elevation Oncology positions in Q4 2021 and 2 closed out, a net change of +13 holders.
- The largest Elevation Oncology buyer in Q4 2021 was Sio Capital Management, an estimated $1.73M added.
- The largest Elevation Oncology seller in Q4 2021 was Boxer Capital, an estimated $3.24M sold.
Based on aggregated 13F filings for Q4 2021.